Terms ending in 2042
Every in-force patent on Genmab A/S's record whose computed term ends in 2042, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,247,065 | Method for Producing a Controlled Mixture of Two or More Different Antibodies In force · High confidence | Genmab A/S | In force | High confidence | |
| US 12,453,781 | Methods of Treating Cancer with a Combination of an Anti-VEGF Antibody and an Anti-Tissue Factor Antibody-Drug Conjugate In force · High confidence | Genmab A/S | In force | High confidence | |
| US 12,246,025 | Methods of Treating Cancer with a Combination of a Platinum-Based Agent and an Anti-Tissue Factor Antibody-Drug Conjugate In force · High confidence | Genmab A/S | In force | High confidence | |
| US 11,814,437 | Antibodies Binding to CD30 and CD3 In force · High confidence | Genmab A/S | In force | High confidence | |
| US 12,747,294 | Anti-Sortilin Antibodies and Use Thereof In force · High confidence | H. Lundbeck A/S | In force | High confidence |
5 of 5 patents shown. Soonest term end first, then patent number.
4 of these are in force and held by Genmab A/S.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.